GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » 5-Year Yield-on-Cost %

SWOBY (Swedish Orphan Biovitrum AB) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB 5-Year Yield-on-Cost %?

Swedish Orphan Biovitrum AB's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Swedish Orphan Biovitrum AB's highest Yield on Cost was 5.00. The lowest was 0.00. And the median was 0.00.


SWOBY's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.185
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost % falls into.



Swedish Orphan Biovitrum AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Swedish Orphan Biovitrum AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Swedish Orphan Biovitrum AB 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).